Osteoclasts Control Osteoblast Chemotaxis Via PDGF-BB/PDGF Receptor Beta Signaling

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2008 Oct 28

PMID 18953417

Citations 50

Authors

Maria Arantzazu Sanchez-Fernandez

Anne Gallois

Thilo Riedl

Pierre Jurdic

Bernard Hoflack

Affiliations

Soon will be listed here.

Abstract

Background: Bone remodeling relies on the tightly regulated interplay between bone forming osteoblasts and bone digesting osteoclasts. Several studies have now described the molecular mechanisms by which osteoblasts control osteoclastogenesis and bone degradation. It is currently unclear whether osteoclasts can influence bone rebuilding.

Methodology/principal Findings: Using in vitro cell systems, we show here that mature osteoclasts, but not their precursors, secrete chemotactic factors recognized by both mature osteoblasts and their precursors. Several growth factors whose expression is upregulated during osteoclastogenesis were identified by DNA microarrays as candidates mediating osteoblast chemotaxis. Our subsequent functional analyses demonstrate that mature osteoclasts, whose platelet-derived growth factor bb (PDGF-bb) expression is reduced by siRNAs, exhibit a reduced capability of attracting osteoblasts. Conversely, osteoblasts whose platelet-derived growth factor receptor beta (PDGFR-beta) expression is reduced by siRNAs exhibit a lower capability of responding to chemotactic factors secreted by osteoclasts.

Conclusions/significance: We conclude that, in vitro mature osteoclasts control osteoblast chemotaxis via PDGF-bb/PDGFR-beta signaling. This may provide one key mechanism by which osteoclasts control bone formation in vivo.

Citing Articles

Citric Acid: A Nexus Between Cellular Mechanisms and Biomaterial Innovations.

Xu H, Yan S, Gerhard E, Xie D, Liu X, Zhang B Adv Mater. 2024; 36(32):e2402871.

PMID: 38801111 PMC: 11309907. DOI: 10.1002/adma.202402871.

Current perspectives on the multiple roles of osteoclasts: Mechanisms of osteoclast-osteoblast communication and potential clinical implications.

Daponte V, Henke K, Drissi H Elife. 2024; 13.

PMID: 38591777 PMC: 11003748. DOI: 10.7554/eLife.95083.

Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases.

Takegahara N, Kim H, Choi Y Exp Mol Med. 2024; 56(2):264-272.

PMID: 38297158 PMC: 10907717. DOI: 10.1038/s12276-024-01157-7.

A novel decellularized matrix of Wnt signaling-activated osteocytes accelerates the repair of critical-sized parietal bone defects with osteoclastogenesis, angiogenesis, and neurogenesis.

Wang X, Ma Y, Chen J, Liu Y, Liu G, Wang P Bioact Mater. 2022; 21:110-128.

PMID: 36093329 PMC: 9411072. DOI: 10.1016/j.bioactmat.2022.07.017.

Nervous System-Driven Osseointegration.

Sun R, Bai L, Yang Y, Ding Y, Zhuang J, Cui J Int J Mol Sci. 2022; 23(16).

PMID: 36012155 PMC: 9408825. DOI: 10.3390/ijms23168893.

References

Glass 2nd D, Karsenty G . Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. Ann N Y Acad Sci. 2006; 1068:117-30. DOI: 10.1196/annals.1346.015. View

Czupalla C, Mansukoski H, Pursche T, Krause E, Hoflack B . Comparative study of protein and mRNA expression during osteoclastogenesis. Proteomics. 2005; 5(15):3868-75. DOI: 10.1002/pmic.200402059. View

Lee S, Rho J, Jeong D, Sul J, Kim T, Kim N . v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med. 2006; 12(12):1403-9. DOI: 10.1038/nm1514. View

Aguila H, Rowe D . Skeletal development, bone remodeling, and hematopoiesis. Immunol Rev. 2005; 208:7-18. DOI: 10.1111/j.0105-2896.2005.00333.x. View

Czupalla C, Mansukoski H, Riedl T, Thiel D, Krause E, Hoflack B . Proteomic analysis of lysosomal acid hydrolases secreted by osteoclasts: implications for lytic enzyme transport and bone metabolism. Mol Cell Proteomics. 2005; 5(1):134-43. DOI: 10.1074/mcp.M500291-MCP200. View

Hartmann C . A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol. 2006; 16(3):151-8. DOI: 10.1016/j.tcb.2006.01.001. View

Yin T, Li L . The stem cell niches in bone. J Clin Invest. 2006; 116(5):1195-201. PMC: 1451221. DOI: 10.1172/JCI28568. View

Rivera G, Antoku S, Gelkop S, Shin N, Hanks S, Pawson T . Requirement of Nck adaptors for actin dynamics and cell migration stimulated by platelet-derived growth factor B. Proc Natl Acad Sci U S A. 2006; 103(25):9536-41. PMC: 1476694. DOI: 10.1073/pnas.0603786103. View

Kronenberg H . PTHrP and skeletal development. Ann N Y Acad Sci. 2006; 1068:1-13. DOI: 10.1196/annals.1346.002. View

10.

Rosen V . BMP and BMP inhibitors in bone. Ann N Y Acad Sci. 2006; 1068:19-25. DOI: 10.1196/annals.1346.005. View

11.

Bruzzaniti A, Baron R . Molecular regulation of osteoclast activity. Rev Endocr Metab Disord. 2006; 7(1-2):123-39. DOI: 10.1007/s11154-006-9009-x. View

12.

Teitelbaum S . Osteoclasts: what do they do and how do they do it?. Am J Pathol. 2007; 170(2):427-35. PMC: 1851862. DOI: 10.2353/ajpath.2007.060834. View

13.

Kaplan R, Psaila B, Lyden D . Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med. 2007; 13(2):72-81. DOI: 10.1016/j.molmed.2006.12.003. View

14.

Maeda Y, Nakamura E, Nguyen M, Suva L, Swain F, Razzaque M . Indian Hedgehog produced by postnatal chondrocytes is essential for maintaining a growth plate and trabecular bone. Proc Natl Acad Sci U S A. 2007; 104(15):6382-7. PMC: 1851055. DOI: 10.1073/pnas.0608449104. View

15.

Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, Boxberger S . Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif. 2007; 40(3):355-66. PMC: 6496321. DOI: 10.1111/j.1365-2184.2007.00438.x. View

16.

Jaganathan B, Ruester B, Dressel L, Stein S, Grez M, Seifried E . Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells. 2007; 25(8):1966-74. DOI: 10.1634/stemcells.2007-0167. View

17.

OSullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D . Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res. 2007; 22(11):1679-89. DOI: 10.1359/jbmr.070719. View

18.

Bennett C, Ouyang H, Ma Y, Zeng Q, Gerin I, Sousa K . Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res. 2007; 22(12):1924-32. DOI: 10.1359/jbmr.070810. View

19.

Bonnelye E, Chabadel A, Saltel F, Jurdic P . Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2007; 42(1):129-38. DOI: 10.1016/j.bone.2007.08.043. View

20.

Kawamata A, Izu Y, Yokoyama H, Amagasa T, Wagner E, Nakashima K . JunD suppresses bone formation and contributes to low bone mass induced by estrogen depletion. J Cell Biochem. 2008; 103(4):1037-45. DOI: 10.1002/jcb.21660. View